Kimberley Brown, PharmD

ViiV Healthcare

Disclosure(s): ViiV Healthcare: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-313) Black Women’s Experiences on Long-Acting Cabotegravir for PrEP: Interim Patient Findings from the EBONI Study
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-332) Screening Practices for HIV and Sexually Transmitted Infections During Cabotegravir Long Acting or Daily Oral Pre-Exposure Prophylaxis Use in the US
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-345) Prevalence of Integrase HIV-1 Drug Resistance Mutations in the United States: 2019-2024
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-371) Few differences in persistence and virologic outcomes across age groups among CAB+RPV LA users: Findings from the OPERA Cohort
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-383) Reasons for discontinuation of CAB+RPV LA for HIV treatment in the OPERA Cohort: A CHORUS survey of healthcare providers
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET